Functional genome screen for therapeutic targets of osteosarcoma

Umio Yamaguchi, Kazufumi Honda, Reiko Satow, Eisuke Kobayashi, Turrent Robert Nakayama, Hitoshi Ichikawa, Ayako Shoji, Miki Shitashige, Mari Masuda, Akira Kawai, Hirokazu Chuman, Yukihide Iwamoto, Setsuo Hirohashi, Tesshi Yamada

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Osteosarcoma (OS) is the most frequent primary malignant bone tumor of children and young adults. Although the introduction of combined neoadjuvant chemotherapy has markedly improved survival, the outcome of OS patients with distant metastasis and/or poor response to chemotherapy is still unsatisfactory. Therefore there is a need to develop new therapeutic agents that suppress OS cell proliferation with higher efficacy. The protein kinases are a family of genes that play critical roles in various signaling pathways. Some cancer cells show addiction to constitutive activation of certain signaling pathways for proliferation and survival. To identify new drug targets for OS, we screened a panel of small interfering RNAs (siRNAs) that target 691 genes encoding human protein kinases and related proteins. We found that different constructs of siRNA specifically targeting polo-like 1 kinase (PLK1) significantly caused mitotic cell cycle arrest and subsequent apoptotic cell death in a variety of OS cell lines. siRNA targeting PLK1 also suppressed the growth of OS xenografts established in immunodeficient mice. Recently, phase I clinical trials of PLK1 chemical inhibitors have been reported. Our results indicate that PLK1 is a promising molecular target for pharmacologic intervention in OS.

Original languageEnglish
Pages (from-to)2268-2274
Number of pages7
JournalCancer Science
Volume100
Issue number12
DOIs
Publication statusPublished - 2009 Dec
Externally publishedYes

Fingerprint

Osteosarcoma
Genome
Small Interfering RNA
Protein Kinases
Therapeutics
Drug Therapy
Clinical Trials, Phase I
Survival
Cell Cycle Checkpoints
Heterografts
Genes
Young Adult
Neoplasms
Cell Death
Cell Proliferation
Neoplasm Metastasis
Bone and Bones
Cell Line
polo-like kinase 1
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yamaguchi, U., Honda, K., Satow, R., Kobayashi, E., Nakayama, T. R., Ichikawa, H., ... Yamada, T. (2009). Functional genome screen for therapeutic targets of osteosarcoma. Cancer Science, 100(12), 2268-2274. https://doi.org/10.1111/j.1349-7006.2009.01310.x

Functional genome screen for therapeutic targets of osteosarcoma. / Yamaguchi, Umio; Honda, Kazufumi; Satow, Reiko; Kobayashi, Eisuke; Nakayama, Turrent Robert; Ichikawa, Hitoshi; Shoji, Ayako; Shitashige, Miki; Masuda, Mari; Kawai, Akira; Chuman, Hirokazu; Iwamoto, Yukihide; Hirohashi, Setsuo; Yamada, Tesshi.

In: Cancer Science, Vol. 100, No. 12, 12.2009, p. 2268-2274.

Research output: Contribution to journalArticle

Yamaguchi, U, Honda, K, Satow, R, Kobayashi, E, Nakayama, TR, Ichikawa, H, Shoji, A, Shitashige, M, Masuda, M, Kawai, A, Chuman, H, Iwamoto, Y, Hirohashi, S & Yamada, T 2009, 'Functional genome screen for therapeutic targets of osteosarcoma', Cancer Science, vol. 100, no. 12, pp. 2268-2274. https://doi.org/10.1111/j.1349-7006.2009.01310.x
Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama TR, Ichikawa H et al. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Science. 2009 Dec;100(12):2268-2274. https://doi.org/10.1111/j.1349-7006.2009.01310.x
Yamaguchi, Umio ; Honda, Kazufumi ; Satow, Reiko ; Kobayashi, Eisuke ; Nakayama, Turrent Robert ; Ichikawa, Hitoshi ; Shoji, Ayako ; Shitashige, Miki ; Masuda, Mari ; Kawai, Akira ; Chuman, Hirokazu ; Iwamoto, Yukihide ; Hirohashi, Setsuo ; Yamada, Tesshi. / Functional genome screen for therapeutic targets of osteosarcoma. In: Cancer Science. 2009 ; Vol. 100, No. 12. pp. 2268-2274.
@article{8a598f438c6346a89cc94042c73d35b2,
title = "Functional genome screen for therapeutic targets of osteosarcoma",
abstract = "Osteosarcoma (OS) is the most frequent primary malignant bone tumor of children and young adults. Although the introduction of combined neoadjuvant chemotherapy has markedly improved survival, the outcome of OS patients with distant metastasis and/or poor response to chemotherapy is still unsatisfactory. Therefore there is a need to develop new therapeutic agents that suppress OS cell proliferation with higher efficacy. The protein kinases are a family of genes that play critical roles in various signaling pathways. Some cancer cells show addiction to constitutive activation of certain signaling pathways for proliferation and survival. To identify new drug targets for OS, we screened a panel of small interfering RNAs (siRNAs) that target 691 genes encoding human protein kinases and related proteins. We found that different constructs of siRNA specifically targeting polo-like 1 kinase (PLK1) significantly caused mitotic cell cycle arrest and subsequent apoptotic cell death in a variety of OS cell lines. siRNA targeting PLK1 also suppressed the growth of OS xenografts established in immunodeficient mice. Recently, phase I clinical trials of PLK1 chemical inhibitors have been reported. Our results indicate that PLK1 is a promising molecular target for pharmacologic intervention in OS.",
author = "Umio Yamaguchi and Kazufumi Honda and Reiko Satow and Eisuke Kobayashi and Nakayama, {Turrent Robert} and Hitoshi Ichikawa and Ayako Shoji and Miki Shitashige and Mari Masuda and Akira Kawai and Hirokazu Chuman and Yukihide Iwamoto and Setsuo Hirohashi and Tesshi Yamada",
year = "2009",
month = "12",
doi = "10.1111/j.1349-7006.2009.01310.x",
language = "English",
volume = "100",
pages = "2268--2274",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Functional genome screen for therapeutic targets of osteosarcoma

AU - Yamaguchi, Umio

AU - Honda, Kazufumi

AU - Satow, Reiko

AU - Kobayashi, Eisuke

AU - Nakayama, Turrent Robert

AU - Ichikawa, Hitoshi

AU - Shoji, Ayako

AU - Shitashige, Miki

AU - Masuda, Mari

AU - Kawai, Akira

AU - Chuman, Hirokazu

AU - Iwamoto, Yukihide

AU - Hirohashi, Setsuo

AU - Yamada, Tesshi

PY - 2009/12

Y1 - 2009/12

N2 - Osteosarcoma (OS) is the most frequent primary malignant bone tumor of children and young adults. Although the introduction of combined neoadjuvant chemotherapy has markedly improved survival, the outcome of OS patients with distant metastasis and/or poor response to chemotherapy is still unsatisfactory. Therefore there is a need to develop new therapeutic agents that suppress OS cell proliferation with higher efficacy. The protein kinases are a family of genes that play critical roles in various signaling pathways. Some cancer cells show addiction to constitutive activation of certain signaling pathways for proliferation and survival. To identify new drug targets for OS, we screened a panel of small interfering RNAs (siRNAs) that target 691 genes encoding human protein kinases and related proteins. We found that different constructs of siRNA specifically targeting polo-like 1 kinase (PLK1) significantly caused mitotic cell cycle arrest and subsequent apoptotic cell death in a variety of OS cell lines. siRNA targeting PLK1 also suppressed the growth of OS xenografts established in immunodeficient mice. Recently, phase I clinical trials of PLK1 chemical inhibitors have been reported. Our results indicate that PLK1 is a promising molecular target for pharmacologic intervention in OS.

AB - Osteosarcoma (OS) is the most frequent primary malignant bone tumor of children and young adults. Although the introduction of combined neoadjuvant chemotherapy has markedly improved survival, the outcome of OS patients with distant metastasis and/or poor response to chemotherapy is still unsatisfactory. Therefore there is a need to develop new therapeutic agents that suppress OS cell proliferation with higher efficacy. The protein kinases are a family of genes that play critical roles in various signaling pathways. Some cancer cells show addiction to constitutive activation of certain signaling pathways for proliferation and survival. To identify new drug targets for OS, we screened a panel of small interfering RNAs (siRNAs) that target 691 genes encoding human protein kinases and related proteins. We found that different constructs of siRNA specifically targeting polo-like 1 kinase (PLK1) significantly caused mitotic cell cycle arrest and subsequent apoptotic cell death in a variety of OS cell lines. siRNA targeting PLK1 also suppressed the growth of OS xenografts established in immunodeficient mice. Recently, phase I clinical trials of PLK1 chemical inhibitors have been reported. Our results indicate that PLK1 is a promising molecular target for pharmacologic intervention in OS.

UR - http://www.scopus.com/inward/record.url?scp=70649112061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649112061&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01310.x

DO - 10.1111/j.1349-7006.2009.01310.x

M3 - Article

C2 - 19725836

AN - SCOPUS:70649112061

VL - 100

SP - 2268

EP - 2274

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -